1. Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature
   Kununya Pimolbutr et al, 2018, BioMed Research International CrossRef
2. Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
   Hely Ollila-Raj et al, 2023, Lung Cancer CrossRef
3. New therapeutic strategies for malignant pleural mesothelioma
   Mara A. Bonelli et al, 2017, Biochemical Pharmacology CrossRef
4. BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state
   Emma M. Rath et al, 2018, PLOS ONE CrossRef
5. Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
   Marjorie G. Zauderer, 2017, Asbestos and Mesothelioma CrossRef
6. Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling
   Zhen Chen et al, 2019, Biochemical and Biophysical Research Communications CrossRef
7. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma
   Ymera Pignochino et al, 2015, BMC Cancer CrossRef
8. Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
   Pedro C. Barata et al, 2019, Investigational New Drugs CrossRef
9. Inhibition of mTOR by temsirolimus overcomes radio‐resistance in nasopharyngeal carcinoma
   Shiyong Huang et al, 2022, Clinical and Experimental Pharmacology and Physiology CrossRef
10. Systematic review of medication related osteonecrosis of the jaw (MRONJ) in patients undergoing only antiangiogenic drug therapy: surgery or conservative therapy?
    R. Sacco et al, 2022, British Journal of Oral and Maxillofacial Surgery CrossRef